These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 14687442)

  • 1. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
    Auriacombe S; Pere JJ;
    Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    McRae TD; Schwam EM
    Curr Med Res Opin; 2002; 18(6):i-iii; author reply iv-vi. PubMed ID: 12442885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alzheimer's disease. Foreword].
    Derquesné C
    Rev Prat; 1998 Nov; 48(17):1871-2. PubMed ID: 9882238
    [No Abstract]   [Full Text] [Related]  

  • 5. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
    Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
    Bianchetti A; Rozzini R; Trabucchi M
    Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
    Gasser US; Gasser T
    MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs for Alzheimer's disease.
    Burns A; Russell E; Page S
    Br J Psychiatry; 1999 Jun; 174():476-9. PubMed ID: 10616624
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
    Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
    Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug treatment for Alzheimer's disease. SMAC's advice on use of donepezil is contradictory.
    Baxter T; Black D; Prempeh H
    BMJ; 1998 Oct; 317(7163):946. PubMed ID: 9841011
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of responders and non-responders to long-term donepezil treatment.
    Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
    Psychogeriatrics; 2010 Jun; 10(2):53-61. PubMed ID: 20738808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.